SQI Diagnostics has raised $4.2 million through a public offering, selling off shares and warrants to bankroll its commercialization plans. The company makes most of its revenue off of companion diagnostics partnerships with drugmakers, but SQI is working toward winning FDA clearance for an in vitro test for celiac disease. More